Patrick Zweidler-McKay
Chief Medical Officer NEOK Bio
Patrick Zweidler-McKay is a Fractional CMO and Clinical Strategy Consultant focusing on supporting ADC Biotechs, with over 26 years of experience in oncology clinical care and research, with key roles in the development of Elahere and Pivekimab sunirine. He previously held clinical leadership roles at ImmunoGen, Abbvie and served as Deputy Department Chair of Pediatrics at MD Anderson Center.
Seminars
- Delving into the IND enabling profiles of bispecific ADCs NEOK001 and 002, emphasizing advantages over monospecific ADCs
- Explaining the unique characteristics of NEOK001 targeting B7-H3+ROR1 including higher need for differentiation amongst B7-H3 ADC landscape
- Breaking down early clinical development strategy and lessons learned from ongoing Phase I bispecific ADC trials
With more and more ADCs entering the clinic, it has never been more important to optimize clinical characterization and development strategies to demonstrate differentiation and benefit oncology patients.
Attend this session to dive into ADC clinical development strategy from bioanalytical characterization to support clinical dosing, understanding mechanisms of ADC resistance, and contextualizing opportunities to maximize differentiation in crowded oncology indications.
Workshop Highlights Include:
- Laying out ADC bioanalytical characterization to support clinical pharmacology, dosing strategy and trial design in early ADC clinical development
- Contextualizing ADC clinical development in an increasingly busy oncology therapeutic landscape: What are the strategies to deliver clinical impact with the bar for success raised?
- Breaking down tumor target expression and ADC resistance mechanisms to optimize approaches to unlock clinical benefit across combination and sequencing approaches
